Skip to Content
Global News Select

Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue

By Matt Grossman


Biogen Inc.'s reported second-quarter revenue and profit declined amid lower royalties from its multiple-sclerosis drug, but the metrics came in above analysts' expectations. Sales of Aduhelm, its recently approved drug for Alzheimer's disease, didn't make a significant contribution in the period.

The Cambridge, Mass.-based biotechnology company posted earnings of $2.99 a share, compared with $9.59 a share a year earlier. Net income attributable to the company was $448.5 million, compared with $1.54 billion, the company said.

Excluding one-time items, the company's adjusted earnings were $5.68 a share. Analysts had been expecting adjusted earnings of $4.55 a share, according to FactSet.

Revenue was $2.78 billion, down from $3.68 billion, the company said. Analysts had been anticipating revenue of $2.61 billion.

Royalties in sales of Ocrevus, a drug for multiple sclerosis, declined by 24% to $1.18 billion. Sales of Spinraza, a drug for spinal muscular atrophy, were up by 1% to $500 million, Biogen said.

Biogen reported $2 million in sales of its Alzheimer's-disease drug Aduhelm. The company said it expects Aduhelm to contribute modest revenue this year, with a ramp-up thereafter.


Write to Matt Grossman at


(END) Dow Jones Newswires

July 22, 2021 07:46 ET (11:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.